Abstract:Ashraf Duzan, BPharm., MS 1,2 ; Xiaodong Gu, Ph.D. 1,3 ; Adam Roberts, Ph.D. 1,3 ; Jennifier Buffa, MS 1,3 ; James Anderson 1,3 , Valentine Gogonea, Ph.D 1,2,3 Stanley L. Hazen, MD, Ph.D. 1,2,3 . 1 Department of Cellular & Molecular Medicine, 3 Center for Microbiome and Human Health, 4 Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195; 2 Department of Chemistry, Cleveland State University, Cleveland, Ohio 44115 Recent clinical research points to trimethylamine N-oxide (TMAO), a gut microbiota generated metabolite, as a biomarker associated with acute thrombotic event and cardiovascular disease risks, and a direct causative contributor to these adverse phenotypes. Our goal in this project is to develop novel microbial enzyme inhibitors that alter the biosynthetic pathway of TMAO in vivo through the selective potent inhibition of gut microbial choline trimethylamine (TMA) lyase activity, the rate limiting step in TMA and TMAO generation in vivo. TMA generation by gut microbiota is predominantly catalyzed by the gut microbial enzyme pair CutC/D, members of the microbial choline utilization ( cut ) gene cluster. We are using structure activity relationships (SAR) to predict new classes of chemical structures as potential efficient inhibitors. Thus, we are exploring the synthesis of new chemical compounds, non-lethal to the gut microbial community, with high inhibitory potency in multiple in vitro assays employing evolutionarily diverse microbial cutC/D (primary and secondary screens), polymicrobial communities (tertiary screens), and for inhibitors that pass the above screening assays, progression to in vivo studies. We are preparing and assessing inhibitors that can work either through irreversible non-competitive or competitive mechanisms, possess appropriate physico-chemical pharmaceutical properties and have minimal systemic exposure to the host in effort to minimize possibility of side effects. Our leading candidates have excellent enzyme blocking efficiency and display good pharmacokinetic/pharmacodynamics properties.

Potential of phenolic compounds and their gut microbiota-derived metabolites to reduce microbial TMA formation: Application of an in vitro fermentation high throughput screening model

Dysbiosis of Gut Microbiota With Reduced Trimethylamine-N-Oxide Level in Patients With Large-Artery Atherosclerotic Stroke or Transient Ischemic Attack.

Phenolic-rich beverages reduce bacterial TMA formation in an ex vivo- in vitro colonic fermentation model

Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis

Dietary phenolics and their microbial metabolites are poor inhibitors of trimethylamine oxidation to trimethylamine N-oxide by hepatic flavin monooxygenase 3

The use of an in-vitro batch fermentation (human colon) model for investigating mechanisms of TMA production from choline, L-carnitine and related precursors by the human gut microbiota

Phenotypic high-throughput screening identifies modulators of gut microbial choline metabolism

Use of dietary phytochemicals for inhibition of trimethylamine N-oxide formation

Enterobacter Aerogenes ZDY01 Attenuates Choline-Induced Trimethylamine N-Oxide Levels by Remodeling Gut Microbiota in Mice

Atherosclerosis and trimethylamine-N-oxide — the gut microbiota potential

Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target

Abstract 178: Development of a New Structural Family of Microbial Choline Trimethylamine Lyase Inhibitors for the Treatment and Prevention of Cardiovascular Disease

Potential correlation between dietary fiber suppresses microbial conversion of choline to trimethylamine and formation of methylglyoxal .

In vivo mechanism of interaction between trimethylamine lyase expresssion and glycolytic pathways

Microbiota Effect on Trimethylamine N-Oxide Production: From Cancer to Fitness-A Practical Preventing Recommendation and Therapies

Reduction of Intestinal Trimethylamine by Probiotics Ameliorated Lipid Metabolic Disorders Associated with Atherosclerosis

Establishing reliable blood biomarkers for trimethylamine N-oxide status in rodents: effects of oral choline challenge, dietary choline and fasting conditions

Effects of Dietary Choline, Betaine, and L-carnitine on the Generation of Trimethylamine-N-oxide in Healthy Mice.

Effect of Choline Forms and Gut Microbiota Composition on Trimethylamine-N-Oxide Response in Healthy Men

Amelioration of TMAO through probiotics and its potential role in atherosclerosis

Gut-Flora-Dependent Metabolite Trimethylamine-N-Oxide Promotes Atherosclerosis-Associated Inflammation Responses by Indirect ROS Stimulation and Signaling Involving AMPK and SIRT1